Good afternoon :)
Place Order
Add to Watchlist

Venus Remedies Ltd

VENUSREM

Venus Remedies Ltd

VENUSREM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹398 cr, stock is ranked 1,891
High RiskStock is 3.50x as volatile as Nifty
292.002.10% (-6.25)
292.002.10% (-6.25)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹398 cr, stock is ranked 1,891
High RiskStock is 3.50x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

Avg

Can be considered moderately valued vs the market

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹398 cr, stock is ranked 1,891
High RiskStock is 3.50x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
11.440.82
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
46.895.970.56%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.

PE Ratio
40.38
1Y Return
1.12%
Buy Reco %
85.29
PE Ratio
28.66
1Y Return
2.75%
Buy Reco %
72.73
PE Ratio
62.75
1Y Return
13.84%
Buy Reco %
68.00
PE Ratio
16.73
1Y Return
12.31%
Buy Reco %
45.16
PE Ratio
48.73
1Y Return
4.48%
Buy Reco %
80.00
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.33%, vs industry avg of 9.04%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.15% to 0.16%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue420.28402.31374.66327.98375.99600.36608.49565.83613.03676.11
Raw Materialssubtract242.04223.58204.84189.67168.45347.94383.50322.95357.35594.07
Power & Fuel Costsubtract4.014.144.294.864.734.584.715.526.35
Employee Costsubtract32.4434.2739.3142.1046.0246.0252.3357.0566.95
Selling & Administrative Expensessubtract57.5678.3079.4154.5267.1595.9985.5492.49100.77
Operating & Other expensessubtract1.069.035.097.1752.338.9811.9817.4710.43
Depreciation/Amortizationsubtract41.6840.2633.8333.9832.0135.2833.5332.3026.4423.71
Interest & Other Itemssubtract37.9834.3735.4325.4113.3413.020.480.120.090.07
Taxes & Other Itemssubtract1.81-4.563.16-1.151.96-13.21-4.3211.3616.1523.42
EPS1.49-14.36-24.87-23.16-8.1050.0431.6919.8821.3226.06
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Venus Remedies Ltd13.990.82
Sun Pharmaceutical Industries Ltd40.385.760.84%
Cipla Ltd28.664.410.89%
Torrent Pharmaceuticals Ltd62.7515.160.91%

Price Comparison

Compare VENUSREM with any stock or ETF
Compare VENUSREM with any stock or ETF
VENUSREM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding41.76%0.00%0.00%1.11%57.13%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

SepDec '23MarJunSepDec '241.03%1.59%1.48%1.06%1.18%1.11%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

VENUSREM has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 23, 2013

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 23, 2013

Cash Dividend

Ex DateEx DateSep 20, 2012

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 20, 2012

Cash Dividend

Ex DateEx DateSep 22, 2011

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 22, 2011

Cash Dividend

Ex DateEx DateSep 23, 2010

Final
Final | Div/Share: ₹3.00

Dividend/Share

3.00

Ex DateEx Date

Sep 23, 2010

News & Opinions
Spotlight
Venus Remedies gains on strategic MET-X partnership

MET-X, a metallo-beta-lactamase (MBL) inhibitor, targets drug-resistant Gram-negative bacteria, a significant concern in India due to high meropenem resistance. Venus Remedies will initiate Phase I trials in India, testing MET-X with meropenem, progressing to Phase II/III trials for drug-resistant complicated urinary tract infections (cUTIs). The company's established expertise in meropenem marketing and manufacturing is crucial for this development. MET-X's broad-spectrum action combats Gram-negative bacteria that resist beta-lactam antibiotics, offering a solution to antibiotic resistance. Clinical trials in India will adhere to international standards (FDA, EMA, MHRA), facilitating global commercialization. The agreement also allows for potential expansion to other MET-X combinations. Venus Remedies is an Indian research-driven pharmaceutical company dedicated to developing innovative solutions to improve patient outcomes. Venus Remedies reported a consolidated net profit surged 186.13% to Rs 19.60 crore on a 23.31% increase in revenue from operations to Rs 176.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Venus Remedies Ltd leads gainers in 'B' group

Stallion India Fluorochemicals Ltd, Bliss GVS Pharma Ltd, BEML Land Assets Ltd and Repro India Ltd are among the other gainers in the BSE's 'B' group today, 05 February 2025.Venus Remedies Ltd surged 20.00% to Rs 348.6 at 12:03 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 7966 shares were traded on the counter so far as against the average daily volumes of 2333 shares in the past one month. Stallion India Fluorochemicals Ltd spiked 14.14% to Rs 107.78. The stock was the second biggest gainer in 'B' group. On the BSE, 5.49 lakh shares were traded on the counter so far as against the average daily volumes of 2.75 lakh shares in the past one month. Bliss GVS Pharma Ltd soared 13.65% to Rs 159. The stock was the third biggest gainer in 'B' group. On the BSE, 1.47 lakh shares were traded on the counter so far as against the average daily volumes of 67230 shares in the past one month. BEML Land Assets Ltd exploded 13.45% to Rs 236.15. The stock was the fourth biggest gainer in 'B' group. On the BSE, 50714 shares were traded on the counter so far as against the average daily volumes of 4522 shares in the past one month. Repro India Ltd advanced 11.58% to Rs 560. The stock was the fifth biggest gainer in 'B' group. On the BSE, 4269 shares were traded on the counter so far as against the average daily volumes of 3197 shares in the past one month. Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Venus Remedies hits the roof after Q3 PAT soars to Rs 20 cr

Profit before exceptional items and tax in Q3 FY25 was at Rs 14.97 crore, up 92.42% from Rs 7.78 crore recorded in Q3 FY24. Exceptional profit stood at Rs 9.91 crore in Q3 FY25. Total expenses advanced 18.79% YoY to Rs 163.92 crore in Q3 FY23. The cost of materials consumed was at Rs 97.52 crore (up 11.69% YoY), while employee benefits expenses stood at Rs 19.55 crore (up 12.68% YoY) during the December 2024 quarter. During Q3 FY25, EBIDTA stood at Rs 20.39 crore, up 41.7% from Rs 14.39 crore posted in corresponding quarter last year. On a nine-month basis, the company's net profit jumped 35.45% to Rs 24.34 crore on 11.48% rise in revenue from operations to Rs 452.92 crore in 9M FY24 over 9M FY23. Venus Remedies is among the 10 leading fixed-dose injectable manufacturers in the world. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit rises 186.13% in the December 2024 quarter

Net profit of Venus Remedies rose 186.13% to Rs 19.60 crore in the quarter ended December 2024 as against Rs 6.85 crore during the previous quarter ended December 2023. Sales rose 23.32% to Rs 176.86 crore in the quarter ended December 2024 as against Rs 143.42 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales176.86143.42 23 OPM %10.388.39 - PBDT20.3814.32 42 PBT14.977.78 92 NP19.606.85 186 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Venus Remedies to announce Quarterly Result

Venus Remedies will hold a meeting of the Board of Directors of the Company on 4 February 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Venus Remedies jumps after renewing the EU GMP certification

The company's manufacturing facility covers, Cephalosporin, Carbapenem and Oncology (liquid& lyophilized injectable) formulations. The company had received its first EU GMP certification in 2007. It has consistently maintained a robust presence in the European market for over 15 years. As one of the leading exporters of Meropenem outside India and with multiple marketing aithoriszations across Europe. Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation. The company's consolidated net profit declined 64.7% YoY to Rs 3.51 crore in Q2 FY25. Net sales fell marginally 0.2% to Rs 167.45 crore in Q2 FY25 as compared with Rs 167.72 crore in Q2 FY24. Powered by Capital Market - Live

1 month agoCapital Market - Live
Live Market Update
Benchmarks trade with limited losses; broader mrkt outperforms

The key equity indices traded with minor losses in mid-afternoon trade. The Nifty traded below the 23,650 mark after hitting the day's high of 23,689.85 in mid-afternoon trade. Oil & gas shares advanced after declining in the past two consecutive trading sessions. At 14:30 IST, the barometer index, the S&P BSE Sensex, declined 131.29 points or 0.17% to 78,116.84. The Nifty 50 index shed 10.50 points or 0.04% to 23,634.40. The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index rose 0.15% and the S&P BSE Small-Cap index advanced 0.52%. The market breadth was positive. On the BSE, 2,114 shares rose and 1,796 shares fell. A total of 127 shares were unchanged. Buzzing Index: The Nifty Oil & Gas index gained 1.19% to 10,757.90. The index fell 0.83% in past two consecutive trading sessions. Oil India (up 3.17%), Oil & Natural Gas Corpn (up 2.75%), Mahanagar Gas (up 2.41%), Indraprastha Gas (up 2.06%), Castrol India (up 1.89%), Indian Oil Corporation (up 1.59%), GAIL (India) (up 1.53%), Aegis Logistics (up 1%), Petronet LNG (up 0.99%) and Hindustan Petroleum Corporation (up 0.81%) advanced. On the other hand, Adani Total Gas (down 2.62%), Gujarat Gas (down 0.53%) and Gujarat State Petronet (down 0.51%) edged lower. Numbers to Track: The yield on India's 10-year benchmark federal paper slipped 0.17% to 6.874 as compared with the previous close of 6.886. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 85.6000, compared with its close of 85.5250 during the previous trading session. MCX Gold futures for the 5 February 2025 settlement rose 0.36% to Rs 76,535. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.19% to 107.92. The United States 10-year bond yield declined 0.68% to 4.514. In the commodities market, Brent crude for February 2025 settlement added 54 cents, or 0.73% to $74.53 a barrel. Stocks in Spotlight: Venus Remedies jumped 4.61% after the company received good manufacturing practice (GMP) certification from Ministry of Health of Moldova for the company's antibiotic -Carbapenem facility. Shares of Adani Wilmar dropped 6.69% and Adani Enterprises (AEL) declined 2.61% after AEL informed that it has signed an agreement with Wilmar International to exit from the joint venture (JV), Adani Wilmar.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Venus Remedies rallies after receiving GMP certificate for antibiotic-Carbapenem facility.

The company said that it is well-positioned to further extend its presence in the eastern European market ensuring access to high quality, effective, and reliable antibiotics for healthcare providers and patients across the region. Venus Remedies is a global pharmaceutical company with a strong focus on fixed dosage injectables. It has a wide range of products and is present in many countries around the world. The company is also committed to research and innovation. The company's consolidated net profit declined 64.7% YoY to Rs 3.51 crore in Q2 FY25. Net sales fell marginally 0.2% to Rs 167.45 crore in Q2 FY25 as compared with Rs 167.72 crore in Q2 FY24. Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Venus Remedies consolidated net profit declines 64.69% in the September 2024 quarter

Net profit of Venus Remedies declined 64.69% to Rs 3.51 crore in the quarter ended September 2024 as against Rs 9.94 crore during the previous quarter ended September 2023. Sales declined 0.16% to Rs 167.45 crore in the quarter ended September 2024 as against Rs 167.72 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales167.45167.72 0 OPM %2.9410.61 - PBDT15.4820.78 -26 PBT9.0714.34 -37 NP3.519.94 -65 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Venus Remedies to table results

Venus Remedies will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Venus Remedies Ltd (VENUSREM) today?

    The share price of VENUSREM as on 11th March 2025 is ₹292. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Venus Remedies Ltd (VENUSREM) share?

    The past returns of Venus Remedies Ltd (VENUSREM) share are
    • Past 1 week: 6.48%
    • Past 1 month: -14.46%
    • Past 3 months: -13.67%
    • Past 6 months: -18.69%
    • Past 1 year: -13.30%
    • Past 3 years: -0.43%
    • Past 5 years: 812.50%

  3. What are the peers or stocks similar to Venus Remedies Ltd (VENUSREM)?
  4. What is the market cap of Venus Remedies Ltd (VENUSREM) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Venus Remedies Ltd (VENUSREM) is ₹398.67 Cr as of 11th March 2025.

  5. What is the 52 week high and low of Venus Remedies Ltd (VENUSREM) share?

    The 52-week high of Venus Remedies Ltd (VENUSREM) is ₹427.90 and the 52-week low is ₹270.25.

  6. What is the PE and PB ratio of Venus Remedies Ltd (VENUSREM) stock?

    The P/E (price-to-earnings) ratio of Venus Remedies Ltd (VENUSREM) is 13.99. The P/B (price-to-book) ratio is 0.82.

  7. Which sector does Venus Remedies Ltd (VENUSREM) belong to?

    Venus Remedies Ltd (VENUSREM) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. How to buy Venus Remedies Ltd (VENUSREM) shares?

    You can directly buy Venus Remedies Ltd (VENUSREM) shares on Tickertape. Simply sign up, connect your demat account and place your order.